Literature DB >> 4047961

Deaths from varicella in infants.

S R Preblud, D J Bregman, L L Vernon.   

Abstract

Onset of maternal varicella up to 5 days before delivery is associated with in utero exposure to varicella and may result in severe infection in the newborn 5 to 10 days after delivery. Since up to 31% of these newborns may die, routine administration of varicella-zoster immunoglobulin to these infants is recommended. Little is known, however, about the risk of death in other infants with postnatal infection. Available epidemiologic data indicate an estimated death/case ratio for children less than 1 year of age 4 times that for 1- to 14-year-olds (8 in 100,000 vs. 2 in 100,000). Since the actual ages for the infant deaths were lacking, it has been impossible to know how many deaths were possibly related to maternal varicella contracted within the 5 days before delivery. Using National Center for Health Statistics data, we analyzed 92 deaths due to varicella in children less than 1 year old reported between 1968 and 1978 (median age, 5.5 months). Only five deaths occurred in newborns (ages 8 hours to 19 days). These data indicate that intrauterine infection accounts for few varicella deaths in infants. Since postnatal infection accounts for the observed increased risk of death in this age group, the need for preventing postnatal varicella in all infants merits further study. However, based on the small number of deaths occurring annually and the low relative risk compared to other high risk groups, routine postexposure administration of varicella-zoster immunoglobulin to all children less than 1 year of age does not seem warranted at this time.

Entities:  

Mesh:

Year:  1985        PMID: 4047961     DOI: 10.1097/00006454-198509000-00013

Source DB:  PubMed          Journal:  Pediatr Infect Dis        ISSN: 0277-9730


  13 in total

1.  Varicella zoster immune globulin use in neonates and infants.

Authors: 
Journal:  Can J Infect Dis       Date:  1996-01

Review 2.  Neonatal innate immunity to infectious agents.

Authors:  László Maródi
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

3.  Impact and costs of varicella prevention in a university hospital.

Authors:  D J Weber; W A Rutala; C Parham
Journal:  Am J Public Health       Date:  1988-01       Impact factor: 9.308

4.  Potent induction of IFN-γ production from cord blood NK cells by the stimulation with single-stranded RNA.

Authors:  Fairuz Mohamed Eljaafari; Hidetoshi Takada; Tamami Tanaka; Takehiko Doi; Shouichi Ohga; Toshiro Hara
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

5.  Waning immunity to varicella in infants of human immunodeficiency virus-seropositive and -seronegative mothers.

Authors:  Shahana A Choudhury; Gwinnett Ladson; Edward R Hills; Frank Hatcher
Journal:  Pediatr Infect Dis J       Date:  2011-09       Impact factor: 2.129

Review 6.  Pregnant workers. A physician's guide to assessing safe employment.

Authors:  J S Feinberg; C R Kelley
Journal:  West J Med       Date:  1998-02

Review 7.  Varicella-zoster virus.

Authors:  A M Arvin
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

8.  Neonatal varicella: A case report.

Authors:  Ak Bhardwaj; Pd Sharma; A Sharma
Journal:  Australas Med J       Date:  2011-06-30

9.  Varicella infection in a neonate with subsequent staphylococcal scalded skin syndrome and fatal shock.

Authors:  Shakal Narayan Singh; Mohammad Tahazzul; Anita Singh; Surabhi Chandra
Journal:  BMJ Case Rep       Date:  2012-08-01

10.  Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease.

Authors:  Yann Mikaeloff; Abbas Kezouh; Samy Suissa
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.